Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.
Adam E SnookTrevor R BaybuttBo XiangTara S AbrahamJohn C FlickingerTerry HyslopTingting ZhanWalter K KraftTakami SatoScott A WaldmanPublished in: Journal for immunotherapy of cancer (2019)
This trial (NCT01972737) was registered at ClinicalTrials.gov on October 30th, 2013. https://clinicaltrials.gov/ct2/show/NCT01972737.